Product Safety & Liability Reporter: Current Reports Index-Summary

PACEMAKERS

– Atrium punctured by dislodged device, claims do not meet pleading standard and preempted (N.D. Tex.), 710
– Company representative directions to physician differ from published warnings, learned intermediary defense (Conn.), 992

PACIFIERS

– Mexico made, recall, 774; BNA monthly recall report, 886

PAIN PUMPS

– Alleged violations of FDA rules not parallel claims, preempted (E.D. La.), 1127
– Continuous intra-articular use of anesthetics, high school athlete charges failure to warn (S.D. Ind.), 243
– Contribution and indemnity from physician sought by maker (E.D. Ky.), 501
– Degeneration of shoulder cartilage, transfer and centralization denied for 2d time, indeterminate number of products and makers (J.P.M.L.), 415
– Direct infusion into joint space, chondrolysis risk, maker had no duty to warn (E.D. Cal.), 736
– Discovery rule tolls statute of limitations (D. Minn.), 1172
– Disposition, 4 of 5 cases (D. Minn.), 1248
– Expert testimony inadmissible, claims for chondrolysis, summary judgment for maker (11th Cir.), 899
– Failure to perform to specifications, compliance with premarket approval requirements, claims preempted (S.D. W.Va.), 1241
– Faulty pleading of product liability claim under state law, third amended complaint filed (N.D. Ohio), 604
– Fraudulent concealment claim fails to meet heightened pleading standards, dismissed (W.D. Pa.), 1131
– Hospital possibly liable as seller or distributor, remanded (D. Mass.), 1275
– I-Flow

– – Bupivacaine use allegedly caused chondrolysis, failure to identify maker, claim allowed (D.R.I.), 632
– – Conspiracy claim, promotion of device for use rejected by FDA (D.N.M.), 1023
– – Drug companies dismissed without prejudice (D. Minn.), 704
– – Expert testimony, risk of administering anesthetic directly into joints, accord (S.D. Ohio), 305
– – Failure to identify makers of products used in shoulders, claims dismissed with leave to amend if able to identify (C.D. Cal.), 396
– – Fraud claims dismissed without prejudice (N.D. Ind.), 1169
– – Intra-articular use, FDA documents re 510(k) clearance admissible (D. Or.), 1103
– – Punitive damage claims

– – – Choice of law issue (N.D. Ill.), 1243
– – – Pleadings sufficient (S.D. Ohio), 1213

– – Transfer of case to plaintiffs' home state of N.C. (D. Minn.), 759
– – Warranty claim time-barred, other claims allowed (D. Colo.), 903

– Intra-articular use, civil conspiracy claims dismissed (D. Or.), 566
– Medtronic, preemption, parallel N.Y. claims, link between good manufacturing practice and cell tumor, drug withdrawal (E.D.N.Y.), 48
– Misconduct alleged in intra-articular use promotion, exemplary damages claim allowed (D. Colo.), 1131
– Morphine toxicity death, parallel state product liability claims (S.D. Tex.), 1047
– Multiple device makers, failure to identify maker, negligence, strict liability, and failure to warn (M.D. Fla.), 212
– Naming 2 companies sufficiently identifies defendant, motion to dismiss denied (N.D. Fla.), 994
– Negligence claim, Minn. not inconvenient forum for Mich. maker (D. Minn.), 1074
– Passive seller, premature to dismiss claims, discovery to determine whether exemption to immunity exists (D. Minn.), 334
– Punitive damages, medication in pump not approved for use in joint space or orthopedic surgery (N.D. Ohio), 333
– Risk information concealment alleged, plaintiff discovery allowed (W.D. La.), 792
– Sensorcaine, shoulder developed further injury, evidence AstraZeneca made first anesthetic after surgery (D. Ct.), 121

PAIN RELIEF PRODUCTS

– Fentanyl patches

See FENTANYL

– Motrin

See MOTRIN

– NSAIDs

See NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)

– Pain pumps

See PAIN PUMPS

– Phenazopyridine, urinary tract analgesic, allergic reaction, substitution of generics (7th Cir.), 100; (U.S., rev den), 1050
– Propoxyphene, drug safety, Public Citizen urges recall, 247
– Tylenol, scientific data or studies showing causal link to cirrhosis (N.Y. Sup. Ct. Kings Cnty.), 99

PAINTS AND COATINGS

– Door handles peeling chrome laceration hazard, NHTSA upgrades probe of 2007 Chevrolet Tahoe, 617
– Fabric protector spray, respiratory hazard, recall, 1138; BNA monthly recall report, 1284
– Lead paint

See LEAD PAINT

– Synthetic stucco

See SYNTHETIC STUCCO

PAXIL

– Birth defects causation alleged

– – Negligence claim against doctor, fraudulent joinder defense (E.D. Pa.), 923
– – Settlement (Pa. Ct. C.P.), 658

– Failure to warn of suicide risks

– – Catholic priest suicide while taking, failure to warn, physician knowledge of risks, medical causation proof admissible (S.D. Ind.), 397
– – In utero exposure, claims that wife's use during pregnancy caused fatal heart defect, limitations period (S.D. Ohio), 399
– – Learned intermediary doctrine, likelihood of prescribing with most current warnings (11th Cir.), 240
– – Preemption, FDA authority ban on state law claims (7th Cir.), 178; decision that FDA would have rejected suicide risk cited (10th Cir.), 242; summary judgment vacated and remanded in 2 cases (10th Cir.), 602
– – Transferring claim to N.Y. where critical events occurred (E.D. Pa.), 10

– Settlements in “vast majority” of cases, GlaxoSmithKline announcement, 728
– Wrongful death suicide suit, summary judgment decision for drugmaker, appeal untimely (10th Cir.), 462; rehearing sought, 497

PCBs

See POLYCHLORINATED BIPHENYLS (PCBs)

PEER REVIEW

– Challenging scientific literature in mass tort and product liability litigation, BNA Insight, 745

PENALTIES

– Children's sweatshirts with drawstrings, untimely reporting alleged, Pro-Pac Distributing agrees to pay civil penalty, 950; Winter Bee, 1253
– Civil

– – CPSC, factors for determining amounts, final rule approved, 253; commissioners insights into vote for rule, 283; costs and frequency of investigations rising, Daiso consent decree, BNA Insight, 693
– – Fireworks, 4 importers agree to pay fine, settle alleged safety violations, 1227
– – NHTSA hike in maximum for school buses, bumper standards, consumer data requests, violation of other standards, 145; final rule, 253

– Importing children's products and toys that violate lead and phthalate levels, importer fined, CPSC accord, 224
– Lead paint, importer fined for distributing toys violating 1978 ban, 147; civil penalty doubled, 609
– Thomas & Friends railway toys, importer fined for violating CPSC lead paint ban, 30

PENNSYLVANIA

– Asbestos

– – Other causes of harm exist, exposure claims reinstated (Pa.), 816
– – Successor liability, standing to pursue constitutional challenges, zone of interest test (Pa.), 1246

– Children's Motrin, Me. law governs punitive damages claim, skin reaction and liver damage alleged (E.D. Pa.), 821
– Design defect, appeals court precedent, foreseeable risks of harm, alternative design, printing press (E.D. Pa.), 237
– Effexor suicide warnings, 10 sets of plaintiffs challenge, preemption rejected (3d Cir.), 918
– Hormone replacement therapy

– – Clinical study publication, causal link between breast cancer and medications, summary judgment in 14 cases reversed (Pa. Super. Ct.), 940
– – Limitations period, breast cancer claim after Provera risk known timely (Pa. Super. Ct.), 20

– Medical monitoring, hazardous substances exposure no manifest physical injury, claims in equity, BNA Insight, 428
– Off-label marketing

– – Fraudulent and deceptive marketing of 12 drugs alleged, class action dismissed (E.D. Pa.), 795
– – Neurontin, class challenge decertified (Pa. Super. Ct.), 62; correction, 103

– Pain pump, fraudulent concealment claim fails to meet heightened pleading standards, dismissed (W.D. Pa.), 1131
– Paxil, birth defects causation alleged

– – Negligence claim against doctor, fraudulent joinder defense (E.D. Pa.), 923
– – Settlement (Pa. Ct. C.P.), 658

– Prempro alleged cause of breast cancer, claims against maker of FDA-approved drug, Mich. fraud-based exception not preempted (E.D. Pa.), 1045
– Redux

– – Non-disclosed risk does not manifest into injury, failure to warn claim (Pa. Super. Ct.), 817
– – Strict liability and negligent design defect claims, disposition (Pa. Super. Ct.), 840

– Wellbutrin XL, generic drug maker failure to warn claims not preempted (E.D. Pa.), 593; interlocutory appeal filed, 657; interlocutory review opposed, 686

PERSONAL CARE PRODUCTS

– Aromatherapy kits, explosion and projectile hazards, JAKKS Pacific and CPSC recall, 1108; BNA monthly recall report, 1198

PERSONAL INJURY

– Indivisible enhanced injury, defective window glass, fact finder apportionment, presumption of non-defectiveness (Utah), 239

PERSONAL WATERCRAFT

– Wrongful death suit, throttle reapplication device and design defect claims, new trial sought (Cal. Super Ct.), 897

PESTICIDES

– Benlate, fern crops damages award overturned, separate trials ordered for Costa Rican farmers (Fla. Dist. Ct. App.), 1238
– Blueberry farmers' crop damages claims, risk misrepresentation (3d Cir.), 838
– Cholinesterase testing of farm workers, electronic results reporting, Cal. governor signs bill, 1026
– Drift from herbicide aerial application damages crops, $17M awarded (D. Idaho), 533
– Dursban

– – Cerebral palsy and neurological problems, causation evidence not established (8th Cir.), 1239
– – Non-Hodgkins lymphoma causation, Cal. medical examiner testimony on exposure (W.D. Pa.), 273

PET PRODUCTS

– Power adapters for beds, fire and burn hazard, Radio Systems recall, 692; BNA monthly recall report, 886
– ProHeart 6, heartworm protection, consumer fraud class action dismissal affirmed (1st Cir.), 597
– Veterinary insulin, class action, failure to warn after FDA warning (N.D. Ohio), 26
– Vetra 3D, flea and tick control, pet owners' class action, seek recall of pyrethrin-containing products (D.N.J.), 303

PHARMACEUTICALS

See also specific names of drugs
– Accutane

See ACCUTANE

– Adderall, failure to warn of heart attack risk, Pa. claims where place of residence, developing, marketing, and selling in Pa. (Pa. Super. Ct.), 329
– Antidepressants

See ANTIDEPRESSANTS

– Avandia

See AVANDIA

– Botox

See BOTOX

– Cholesterol reduction

See CHOLESTEROL REDUCTION DRUGS

– Cold remedies

See COLD REMEDIES
– – Cough suppressants

See COUGH SUPPRESSANTS

– Contraceptives

See CONTRACEPTIVES

– Cough suppressants

See COUGH SUPPRESSANTS

– Diabetes medications

See DIABETES

– Diet drugs

See DIET DRUGS

– Dietary supplements

See VITAMINS AND DIETARY SUPPLEMENTS

– Digitek

See DIGITEK

– Dopamine agonists, Requip, Parkinson's disease, failure to warn, pathological gambling (5th Cir.), 297
– Erectile dysfunction

See ERECTILE DYSFUNCTION

– Fentanyl patches

See PAIN RELIEF PRODUCTS

– Fraudulent and deceptive marketing of 12 drugs alleged, class action dismissed (E.D. Pa.), 795
– Gadolinium-based contrast agent, renal insufficiency, teenager's claims allowed (N.Y. Sup. Ct.), 420
– Generic drugs

See GENERIC DRUGS

– Heparin

See HEPARIN

– Hormone therapy

See HORMONE REPLACEMENT THERAPY (HRT)

– Imported, FDA program allows better targeted inspections, launch, 147
– Labeling

See LABELING

– Learned intermediary doctrine defense in litigation, history and survey of states, BNA Insight, 544
– Meridia, voluntary withdrawal from U.S. market by Abbott Labs, 1076
– Metoprolol, private right of action for adulterated product, Mo. law preemption (E.D. Mo.), 41
– Mylotarg, Pfizer voluntarily withdraws leukemia drug, 659
– Neurontin

See NEURONTIN

– Pain relief

See PAIN PUMPS; PAIN RELIEF PRODUCTS

– Pondimin

See DIET DRUGS

– Preemption

See PREEMPTION

– Pregnancy, collaboration with private researchers to study safety of prescription drugs, 28
– Proton pump inhibitors, FDA warning, 569
– Remicade

See TNF BLOCKERS

– Sentinel, post market drug safety program, priority on patient privacy, 72
– Seroquel

See SEROQUEL

– Side effects, FDA proposes rule augmenting existing requirements, 335
– Steroids

See STEROIDS

– Vaccines

See VACCINES

– Viagra

See VIAGRA

– Vioxx

See VIOXX

– Zyprexa

See ZYPREXA

PHENAZOPYRIDINE

– Urinary tract analgesic, allergic reaction, substitution of makers, pharmacy duty (7th Cir.), 100; (U.S., rev den), 1050

PHENYTOIN SODIUM

– Skin reaction from use alleged, sufficient claims stated against maker (S.D. Miss.), 1023

PhIP

– Grilled chicken warning, suit reinstated (Cal. Ct. App.), 870; (Cal., rev den), 1130

PHTHALATES

– Children's products

– – Advisory panel, CPSC appoints scientists, 30; health effects, toys and child care articles, first meeting scheduled, 340; first meeting convenes, 402; second meeting scheduled, 614; time changes, second meeting, 691; tentative agenda discussed for Dec. meeting, 1194
– – Component parts testing and testing certification, proposed rule, 506
– – Importer fined for exceeding rules, CPSC accord, 224

PICKUP TRUCKS

See TRUCKS

PIPELINES

– Oil and gas

See OIL AND GAS

PLEADINGS

– New standards, ABA panel, 142
– Notice Pleading Restoration Act

See LEGISLATION, FEDERAL, S 1540

– Open Access to Courts Act

See LEGISLATION, FEDERAL, HR 4115

– Strict liability, heightened standards, Proceed mesh hernia patch defect (M.D. Fla.), 119

PLUMBING EQUIPMENT

– Drain cleaner caused facial burns, adequacy of warnings and design defect (N.Y. App. Div.), 47
– Plastic pipes with brass fittings MDL, building owners class certification (D. Minn.), 499

POLYCHLORINATED BIPHENYLS (PCBs)

– Fish oil supplements, environmental and public health groups seek warning labels (Cal. Super. Ct.), 219

POOLS

See SWIMMING POOLS AND SPAS

PORTLAND CEMENT

– Burn warning inadequate (E.D.N.Y.), 187

PREEMPTION

– Asbestos exposure, railroad workers

– – FRSA, strict liability claim (Pa. Super. Ct.), 42
– – Locomotive Inspection Act, maintenance facility worker's widow (3d Cir.), 965

– Cell phones, radio frequency radiation emissions unsafe, claims preempted (3d Cir.), 1122
– Challenges to plaintiff's complaints, ABA conference, viability of claims, 142
– Cochlear implants adulterated devices, parallel claims not preempted (N.D. Tex.), 705
– Cymbalta, suicide warning risks inadequate, claim not preempted (D.S.D.), 1046; learned intermediary doctrine, judgment for maker, 1102
– Cypher stent, design defect claims preempted, manufacturing defect and failure to warn claims allowed (N.J. Super. Ct. App. Div.), 789
– Designated seating position rule, auto makers given more time to comply, preemption provision removed, 13
– Effexor suicide warnings, 10 sets of plaintiffs challenge (3d Cir.), 918
– Endometrial ablation device, preemption of state tort claims (W.D. La.), 868
– Federal Motor Vehicle Safety Standard 205

– – Airport shuttle failure to have seat belts and tempered glass (Tenn. Ct. App.), 298
– – Same decision as other jurisdictions, rollover ejection death (S.C.), 814
– – Window glazing, claims for failure to meet in rollover injury, Hyundai Sonata (W.D. Okla.), 93

– Fentanyl, punitive damages claim against maker of FDA-approved drug, fraud-based exception not preempted (D. Utah), 991
– FFDCA

– – Effexor, failure to warn, learned intermediary defense (W.D. Pa.), 214
– – Fraud exception for federally approved drug label, skin reaction to Motrin (N.D. Tex.), 115
– – Levine ruling

– – – Over-the-counter drug, Tylenol Cold heat-related illness risk, preemption of failure to warn claim (Fla. Dist. Ct.), 49; (U.S., rev sought), 1241
– – – Paxil, inadequate warning of suicide risk, FDA authority ban on state law claims (7th Cir.), 178; both parties cite decision that FDA would have rejected suicide risk (10th Cir.), 242; summary judgment vacated and remanded in 2 cases (10th Cir.), 602

– – Medical Device Amendments

See Medical Device Amendments to FFDCA, this heading

– – Minocycline acne treatment, teenager vision loss, generic drug maker defense (M.D. Ga.), 276
– – Negligence per se, state law damages claim, knee implant manufacturing defect, lubricating oil prevented bonding (6th Cir.), 624
– – Redux maker negligence in bringing product to market, claim not preempted (6th Cir.), 894; (rehear den), 1099
– – Wellbutrin XL, generic drug maker failure to warn claims not preempted (E.D. Pa.), 593; interlocutory appeal filed, 657; interlocutory review opposed, 686

– FIFRA, blueberry farmers' crop damages claims, pesticides risk misrepresentation (3d Cir.), 838
– Good manufacturing practice requirements

– – Adulterated generic metaprolol, Mo. merchantability law, private right of action (E.D. Mo.), 41
– – Parallel N.Y. claims, link between federal violation and cell tumor, pain pump, drug withdrawal (E.D.N.Y.), 48

– Hip implant received FDA premarket approval, 2 theories bar claims against maker (N.D. Tex.), 941
– Hip prosthesis component part premarket approval, defect alleged, claims preempted (D. Idaho), 1170
– Intraocular lens implant, contamination alleged, product liability claims (Ill. App. Ct.), 901
– Lamisil, failure to warn claim against maker of FDA-approved drug, Tex. fraud-based exception not preempted (D.N.J.), 967
– Medical Device Amendments to FFDCA

– – Abdominal aortic graft device

– – – Fraudulent concealment claims, no fraud-on-the-FDA (Cal. Cir. Ct.), 162; (U.S., rev den), 1275
– – – Investigational device exemption, claims preempted (Cal. Ct. App.), 1217

– – Balloon catheter, angioplasty, Ky. law claims, negligent design and manufacture (E.D. Ky.), 215
– – Defibrillators Sprint Fidelis leads (Cal. Ct. App.), 1130
– – Degeneration of shoulder cartilage, transfer and centralization denied for 2d time, indeterminate number of products and makers (J.P.M.L.), 415
– – Hip prosthesis

– – – Component part passed premarket approval, Tex. tort claims barred (S.D. Tex.), 439
– – – Parallel claims re Trident system preempted (S.D.N.Y.), 1021
– – – Recalls and warning letters as basis for parallel claims, Trident system, no preemption (E.D. Mo.), 1272
– – – Strict liability, negligence, and breach of warranties, Ohio law claims barred (M.D. Fla.), 333
– – – Warning letters sent by FDA, discussion sufficiency to state product liability claim (N.D. Ohio), 359

– – Pacemaker dislodges and punctures heart, claims do not meet pleading standard and preempted (N.D. Tex.), 710
– – Parallel claims, claim linking FDA compliance failures to hip prothesis failure not barred (E.D. Tenn.), 625
– – Seprafilm, strict liability claims, non-preempted parallel claims (N.D. Ill.), 274
– – Transoral Gastroplasty Stapling System, investigational device exemption, claims preempted (E.D.N.Y.), 1240
– – Vagus nerve stimulation system

– – – Breach of warranty and manufacturing claims (3d Cir.), 822
– – – Manufacturing defect, FDA approved manufacture (D.N.J.), 155

– Medical Device Safety Act

See LEGISLATION, FEDERAL, HR 1346, S 540

– Metoclopramide, failure to warn claims

See METOCLOPRAMIDE

– NTMVSA, gross negligence, strict liability, and derivative claims, preemption, failure to install side air bags (D. Haw.), 207
– Organic milk certification and false claims, state law claims status (8th Cir.), 995
– Pain pumps

– – Alleged violations of FDA rules not parallel claims, preempted (E.D. La.), 1127
– – Failure to perform to specifications, compliance with premarket approval requirements, claims preempted (S.D. W.Va.), 1241
– – Morphine toxicity death, parallel state product liability claims (S.D. Tex.), 1047

– Prempro alleged cause of breast cancer, claims against maker of FDA-approved drug, Mich. fraud-based exception not preempted (E.D. Pa.), 1045
– Regulatory compliance defense use to satisfy legal obligations and avoid liabilities, BNA Insight, 576
– Seat belts, lap/shoulder or lap-only type installation in certain seating positions, motor vehicle safety standard implied preemption (U.S., rev grant), 558; (brief filed), 815; (respondents' brief filed), 988; (oral arg), 1144
– Spinal cord stimulator, class III classification, defective design claim (Miss.), 1071
– Tort law of states, ABA resolution seeks clarification, 846
– Vaccine Act, DPT vaccine, design defect claim bar (U.S., rev grant), 235; (brief filed), 595; (amicus briefs filed, support family), 629; (respondent's brief filed), 787; (amicus briefs filed, support manufacturer), 866; (oral arg), 1064
– Zero trans fat labeling, Hostess snack foods, class action dismissed (C.D. Cal.), 1164

PREGNANCY

– Safety of prescription drugs, FDA collaboration with private researchers to study, 28

PREMARIN

– Breast cancer causal link, expert testimony fails Daubert admissibility test (E.D. Ark., D. Minn.), 946
– Forum non conveniens, Fla. woman's suit transferred (D. Minn.), 1152
– HRT, claims for design defects, testing and inadequate warnings, removal to federal court for diversity (E.D. Tex.), 27

PREMPRO

– Breast cancer from use alleged, claims against maker of FDA-approved drug, Mich. fraud-based exception not preempted (E.D. Pa.), 1045
– Class action previously filed tolls limitations period, claims not time-barred (E.D. Va.), 659; verdict, 1275
– Forum non conveniens, Fla. woman's suit transferred (D. Minn.), 1152
– Inadequate warning of risks, damages award (Pa. Ct. C.P.), 184
– Joinder claims against drug makers, logical relationship between makers and users (8th Cir.), 66
– Negligence, failure to warn of risk, proximate cause (Pa. Ct. C.P.), 211
– Risk warning adequate, breast cancer, Wyeth exonerated (E.D. Ark.), 1129
– Short-term use and breast cancer link, expert testimony admissible (D.P.R.), 1242

PRESCRIPTION DRUGS

See PHARMACEUTICALS; specific names

PRIVACY

– Food and Drug Administration

– – Public disclosure draft proposals, potential impact on product liability litigation, 829
– – Sentinel, post market drug safety program, priority on confidentiality of patient data patient, 72

– Medical records

See MEDICAL RECORDS

– Social media sites, federal agencies use to encourage public participation, OMB guidance, 690

PRIVILEGED COMMUNICATIONS

– ObTape Transobdurator sling, discovery of data on competitive product (M.D. Ga.), 97; maker's motion to exclude expert witness who formerly worked for maker, 362; fact issues of design or manufacturing defects and warnings raised but no warranty claims without privity, 444

PROPAFOL

– Hepatitis C contracted from syringes reuse during colonoscopy, damages awarded (Nev. Dist. Ct.), 496

PROPOXYPHENE

– Drug safety, Public Citizen urges recall, 247

PROSTHESES

– Hip replacements

See HIP PROSTHESES

– Knee replacements

See KNEE IMPLANTS

PROTON PUMP INHIBITORS

– Bone fractures risk possible, FDA warning, 569

PROVERA

– Forum non conveniens, Fla. woman's suit transferred (D. Minn.), 1152
– HRT, breast cancer claim after risk known timely (Pa. Super. Ct.), 20

PROZAC

– Generic drug maker failure to warn claims, preemption, suicide under treatment (C.D. Cal.), 354

PUBLIC NUISANCE DOCTRINE

– Growth in litigation, relationship to “political question” doctrine, BNA Insight, 666
– Lead paint suit, pigment makers litigation costs denied (R.I. Super. Ct.), 590

PUERTO RICO

– Prempro, short-term use and breast cancer link, expert testimony admissible (D.P.R.), 1242

PUNITIVE DAMAGES

– Children's Motrin, Me. law governs claim, skin reaction and liver damage alleged (E.D. Pa.), 821
– Failure to show Ohio law applied to pain pump approved by FDA, medication not approved for use in joint space or during orthopedic surgery (N.D. Ohio), 333
– Fentanyl, claim against maker of FDA-approved drug, fraud-based exception not preempted (D. Utah), 991
– Hip implant fails, summary judgment denied (W.D. Okla.), 762
– HRT alleged cause of breast cancer

– – Punitive damages retrial (U.S., opposition brief filed), 568; (rev den), 655
– – $35M award upheld (Nev.), 1207

– Low-tar Merit cigarettes suit, new trial ordered (Or.), 702
– Pain pumps

– – Choice of law issue (N.D. Ill.), 1243
– – Pleadings sufficient (S.D. Ohio), 1213

– Propafol, hepatitis C contracted from syringes reuse during colonoscopy, damages awarded (Nev. Dist. Ct.), 496

PYRETHRIN

– Flea and tick control, pet owners' class action, seek recall of products containing, clearer warnings, EPA (D.N.J.), 303